1-20 of 236
Sung-soo Yoon
Close
Sort by
Journal Articles

T-Cell Depletion with Both Reduced Dose Anti-Thymocyte Globulin and Reduced Dose Post-Transplant Cyclophosphamide in Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Leukemia and Myelodysplatic Syndrome

Junshik Hong, Dong Hyun Kim, Ja Min Byun, Dongyeop Shin, Youngil Koh, Inho Kim, Sung-Soo Yoon, Hyun Jung Lee, Jung Lim Lee
Journal: Blood
Blood (2023) 142 (Supplement 1): 7000.
https://doi.org/10.1182/blood-2023-185845
Published: 2023
Journal Articles

A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit: Results from 12-Month Core Study

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-Won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park
Journal: Blood
Blood (2023) 142 (Supplement 1): 4575.
https://doi.org/10.1182/blood-2023-184431
Published: 2023
Journal Articles

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

Sung-Soo Yoon, Dongyeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yoo Jin Lee, Joseph Clarey, Gi-Jun Sung, Kyung-Ah Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, JeongHyeok Yoon, Bao Nguyen, Li Li, Donald Small
Journal: Blood
Blood (2023) 142 (Supplement 1): 4283.
https://doi.org/10.1182/blood-2023-185606
Published: 2023
Journal Articles

Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone (PCD) Versus Pomalidomide Dexamethasone (PD) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study

Yang Song, Jin Seok Kim, CS Chim, Je-Jung Lee, Sung-Soo Yoon, Soo Chin Ng, Gin Gin Gan, Hiroshi Handa, Wei-Ying Jen, Xinhua Li, Yogesh Mahadev Pokharkar, Brian GM Durie, Wee-Joo Chng
Journal: Blood
Blood (2023) 142 (Supplement 1): 1009.
https://doi.org/10.1182/blood-2023-184723
Published: 2023
Journal Articles

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

Ji Hyun Lee, Chang-Ki Min, Jae-Cheol Jo, Yoo Jin Lee, Jin Seok Kim, Hyun-Seok Uhm, Jong Heon Jung, Joon Ho Moon, Hee Jeong Cho, Myung-won Lee, Sung-Soo Yoon, Ja Min Byun, Jae Hoon Lee, Je-Jung Lee, Sung-Hoon Jung, Ho-Jin Shin, Do Young Kim, Jun Ho Yi, Seung-Shin Lee, Young Rok Do, Dok Hyun Yoon, Hyungwoo Cho, Won-Sik Lee, Ho Sup Lee, Jieun Uhm, Hyo Jung Kim, Hee Ryeong Jang, Sung-Hyun Kim, Kihyun Kim
Journal: Blood
Blood (2023) 142 (Supplement 1): 6675.
https://doi.org/10.1182/blood-2023-174439
Published: 2023
Journal Articles

A Phase 2 Study of Daratumumab in Combination with Thalidomide and Dexamethasone in Relapsed and / or Refractory Myeloma: A Report from the Asian Myeloma Network

Wei-Ying Jen, Melissa Ooi, Sanjay De Mel, Cinnie Soekojo, Sung-Soo Yoon, Xinhua Li, Neha Awasthi, Sarah M Burkill, Brian GM Durie, Wee-Joo Chng
Journal: Blood
Blood (2023) 142 (Supplement 1): 2009.
https://doi.org/10.1182/blood-2023-180017
Published: 2023
Journal Articles

Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Naval Daver, Kyoo Hyung Lee, Yunsuk Choi, Brian A. Jonas, Martha Arellano, Paul B. Koller, Chul W. Jung, Sang Kyun Sohn, Amir T. Fathi, Jeong-Ok Lee, Sung-Soo Yoon, Justin M. Watts, Pankit Vachhani, Ho-Jin Shin, Jia Hu, Ranjeet Sinha, Nawazish Khan, William G. Rice, Rafael Bejar
Journal: Blood
Blood (2023) 142 (Supplement 1): 162.
https://doi.org/10.1182/blood-2023-182296
Published: 2023
Journal Articles

Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data

Swami P. Iyer, Sabarish R. Ayyappan, Irl Brian Greenwell, Won Seog Kim, Seung Tae Lee, Jin Seok Kim, Won-Sik Lee, Youngwoo Jeon, William Johnson, Utpal P. Dave, Sung-Soo Yoon, Ka-Won Kang, Florent Carrette, Julien Viotti, A.J. Leyco, Marianna Muller, Steven M. Horwitz
Journal: Blood
Blood (2023) 142 (Supplement 1): 3072.
https://doi.org/10.1182/blood-2023-172537
Published: 2023
Journal Articles

Treatment of Relapsed/Refractory Hgbcl and Bukitt's Lymphoma with c-Myc Rearrangement: A Multi-Center, Open-Label, Phase 2 Study of PC-002 (SepB), a First-in-Class Deubiquitinase Inhibitor Inducing Myc Degradation

Sung-Soo Yoon, Zhiming Li, Keshu Zhou, Xiaoxi Zhou, Ye Guo, Huilai Zhang, Ki-Seong Eom, Seok Jin Kim, Sung Yong Oh, Sung-Nam Lim, Hagop Youssoufian, Vernon Jiang, Zhanchun Huang, Georgina Kilfoil, Xin Wang, Zhixiang Cao, Xiang LI, Yihai Lin, Alexander Wu, Yiyou Chen, Yuqin Song
Journal: Blood
Blood (2023) 142 (Supplement 1): 1754.
https://doi.org/10.1182/blood-2023-190995
Published: 2023
Journal Articles

Distinct Genetic Features in Peripheral Blood Represent the Characteristics of Circulating Plasma Cells in Primary Plasma Cell Leukemia

Youngeun Lee, Nuri Lee, Sung-Soo Yoon, Jong Hyun Yoon, Dong Soon Lee
Journal: Blood
Blood (2023) 142 (Supplement 1): 3349.
https://doi.org/10.1182/blood-2023-179646
Published: 2023
Journal Articles

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Elizabeth L. Budde, Nancy L. Bartlett, Pratyush Giri, Stephen J. Schuster, Sarit Assouline, Sung-Soo Yoon, Keith Fay, Matthew J. Matasar, Norma C. Gutierrez, Paula Marlton, Martin Dreyling, Dok Hyun Yoon, Georg Hess, John Radford, Volker Wiebking, Shen Yin, Eva Cybulski, David C. Turner, Huang Huang, Mingzhu Zhou, Elicia Penuel, Michael C. Wei, Laurie H. Sehn
Journal: Blood
Blood (2022) 140 (Supplement 1): 3753–3755.
https://doi.org/10.1182/blood-2022-157729
Published: 2022
Journal Articles

Dose-Exposure-Response Relationships of Biomarkers and Efficacy Measures with Iptacopan, a Complement Factor B Inhibitor, in Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) with or without Concomitant Anti-C5 Therapy

Antonio Risitano, Régis Peffault de Latour, Eng Soo Yap, Lily LL Wong, Bor-Sheng Ko, Sung-Soo Yoon, Alexander Roeth, Irina Baltcheva, Julie Milojevic, Niamh Fagan, Kenneth Kulmatycki, Prasanna K Nidamarthy, Guido Junge, Jun Ho Jang
Journal: Blood
Blood (2022) 140 (Supplement 1): 5803–5804.
https://doi.org/10.1182/blood-2022-160114
Published: 2022
Journal Articles

Pursuing the Clonal Dynamics of Minimal Residual Disease (MRD) in Relapsed and Refractory Acute Myeloid Leukemia

Dongchan Kim, Hyojin Song, Sung-Soo Yoon, Daehyeon Gwak, Hongseok Yun, Dong-Yeop Shin
Journal: Blood
Blood (2022) 140 (Supplement 1): 11819–11820.
https://doi.org/10.1182/blood-2022-163023
Published: 2022
Journal Articles

Role of Autologous or Allogeneic Stem Cell Transplantation in Patients with Peripheral T Cell Lymphomas (PTCLs)

Dong Won Baek, Sr., Je-Hwan Lee, Ho Joon Im, Juhyung Kim, Joon Seong Park, Deok-Hwan Yang, Sung-Hyun Kim, Yeung-Chul Mun, Jae Hoon Lee, Ho Sup Lee, Ka-Won Kang, Chuhl Joo Lyu, Seong Kyu Park, Jong Ho Won, Chul Won Jung, Keon Hee Yoo, Sung-Soo Yoon, Soo-Mee Bang, Jae-Cheol Jo, Joon Ho Moon, Sang Kyun Sohn
Journal: Blood
Blood (2022) 140 (Supplement 1): 6592–6593.
https://doi.org/10.1182/blood-2022-171149
Published: 2022
Journal Articles

A Prospective Randomized Study for Optimal Red Blood Cell Use Patients with Acute Myeloid Leukemia Receiving Dose Intensive Chemotherapy

Ja Min Byun, Junshik Hong, Dong-Yeop Shin, Youngil Koh, Sung-Soo Yoon, Inho Kim, Hyungsuk Kim
Journal: Blood
Blood (2022) 140 (Supplement 1): 81–82.
https://doi.org/10.1182/blood-2022-157619
Published: 2022
Journal Articles

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Carmelo Carlo-Stella, Rita Mazza, Salomon Manier, Thierry Facon, Sung-Soo Yoon, Youngil Koh, Simon J Harrison, Jeremy Er, Antonio Pinto, Francesco Volzone, Giulia Perrone, Paolo Corradini, Titouan Cazaubiel, Cyrille Hulin, Cyrille Touzeau, Philippe Moreau, Enrique M. Ocio, Carmen Maria Montes Gaisan, Rakesh Popat, Sarah Leong, Fritz Offner, Paula Rodriguez Otero, Ana Alfonso-Pierola, Ann-Marie E Bröske, Iryna Dekhtiarenko, Hans-Joachim Helms, Sara Belli, Eva Rossmann, Tanja Fauti, Jan Eckmann, Tom Moore, Meike Schneider, Wolfgang Jacob, Martin Weisser, Martin Hutchings, Caroline Hasselbalch Riley
Journal: Blood
Blood (2022) 140 (Supplement 1): 397–399.
https://doi.org/10.1182/blood-2022-157988
Published: 2022
Journal Articles

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Keith W. Pratz, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Walter Fiedler, Kazuhito Yamamoto, Jianxiang Wang, Sung-Soo Yoon, Ofir Wolach, Jun-Ho Jang, Su-Peng Yeh, Grace Ku, Ying Zhou, Brenda Chyla, Jalaja Potluri, Courtney D. DiNardo
Journal: Blood
Blood (2022) 140 (Supplement 1): 529–531.
https://doi.org/10.1182/blood-2022-158518
Published: 2022
Journal Articles

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

Genevive H. Hernandez, John So, Kathryn A. Logronio, Maya F. Kotturi, Won Seog Kim, Philippe Armand, Chan Y. Cheah, Ajay K. Gopal, Ian W. Flinn, Gareth P. Gregory, Matthew J. Matasar, Loretta J. Nastoupil, Catherine S. Diefenbach, Sung-Soo Yoon, Matthew Ku, Ibrahim Qazi, Maya K. Leabman, Iris Sison, Bruce A. Keyt, Chris H. Takimoto, Thomas J. Manley, Elizabeth L. Budde
Journal: Blood
Blood (2022) 140 (Supplement 1): 6436–6438.
https://doi.org/10.1182/blood-2022-163235
Published: 2022
Journal Articles

A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study

Sung-Soo Yoon, Dong-Yeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yunsuk Choi, Joseph Clarey, Jeejin Im, Suntae Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, Jeong Hyeok Yoon, Bao Nguyen, Li Li, Donald Small
Journal: Blood
Blood (2022) 140 (Supplement 1): 3365–3366.
https://doi.org/10.1182/blood-2022-165000
Published: 2022
Journal Articles

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Aaron T. Gerds, Ruben Mesa, Alessandro M Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela Lazaroiu, Miklos Egyed, Maria Laura Fox, Donal P. McLornan, Andrew Charles Perkins, Sung-Soo Yoon, Vikas Gupta, Jean-Jacques Kiladjian, Rafe Donahue, Jun Kawashima, Srdan Verstovsek
Journal: Blood
Blood (2022) 140 (Supplement 1): 1514–1517.
https://doi.org/10.1182/blood-2022-162783
Published: 2022